؉ Th-1 development through the activation of the second messenger STAT4 and the subsequent expression of T-bet. In addition, type I IFN (IFN-␣␤), secreted primarily during viral and intracellular bacterial infections, can promote STAT4 activation in human CD4 ؉ T cells. However, the role of IFN-␣␤ in regulating Th1 development is controversial, and previous studies have suggested a species-specific pathway leading to Th1 development in human but not mouse CD4 ؉ T cells. In this study, we found that although both IFN-␣ and IL-12 can promote STAT4 activation, IFN-␣ failed to promote Th1 commitment in human CD4
D uring infections, innate cytokines direct the development of CD4
ϩ T cells toward effector Th subsets that secrete distinct cytokines. This process is initiated by pathogenassociated molecular patterns (PAMPs) 4 that are recognized by specific TLRs expressed within professional APC subsets (1, 2) . In cases of bacterial infections, PAMPs such as peptidoglycan and LPS are sensed by TLRs 2 and 4, which are expressed predominantly by monocyte-derived dendritic cells (3) . As a consequence, monocyte-derived dendritic cells secrete high levels of IL-12, which directly promotes CD4 ϩ Th1 development (4, 5) . In contrast, virus-derived PAMPs such as double-stranded and singlestranded RNA signal through TLRs 3 and 7, respectively, both of which are potent inducers of type I IFN (IFN-␣␤) (1, 6) . Thus, IL-12 and IFN-␣␤ represent two critical innate cytokines that provide instructive cues for adaptive T cell responses (7) .
A role for IL-12 in promoting Th1 development has been well established (5) . IL-12 signaling promotes the phosphorylation of STAT4 (8, 9) , which is required for Th1 commitment (10) . Further, IL-12-dependent STAT4 activation is conserved across species, and disruptive mutations in this signaling pathway significantly impair Th1 responses in both mice (10, 11) and humans (12) . Likewise, early reports demonstrated a potential role for IFN-␣␤ in promoting Th1 development in human (h)PBMCs (13, 14) . These initial studies were followed by findings that IFN-␣, like IL-12, could promote STAT4 activation in human lymphocytes (15) (16) (17) . These early reports concluded that IFN-␣␤ could directly regulate Th1 commitment in CD4 ϩ T cells through the activation of STAT4 (18) .
However, unlike IL-12, the role of IFN-␣␤ in promoting Th1 development has been met with considerable controversy. Initial reports demonstrating IFN-␣␤-dependent STAT4 activation and Th1 development were performed with hPBMCs or with human T and NK cell lines (13) (14) (15) . In parallel studies with murine T cells, IFN-␣␤ was insufficient to promote Th1 development (17, 19) or activate STAT4 when compared with human CD4 ϩ T cells (16, 17) , indicating a potential species-specific role for IFN-␣␤ in regulating Th1 development. Further, human STAT2 was implicated in facilitating STAT4 recruitment to the human IFN-␣␤ receptor (IFNAR) complex in a species-specific manner (16, 20) . These findings seemed to explain the presumed ability of IFN-␣␤ to promote STAT4 activation and Th1 development in human but not in murine CD4
ϩ T cells. However, CD4 ϩ T cells from STAT2 knock-in mice that expressed a humanized Stat2 gene failed to exhibit either STAT4 phosphorylation or Th1 commitment in response to IFN-␣␤ activation (21) . These results suggested that although human STAT2 was required for STAT4 activation in human cells, it was not sufficient to restore this pathway when expressed in the context of the murine IFNAR.
Recent studies have called this species-specific pathway into question (22, 23) . Biron and colleagues demonstrated that IFN-␣␤ could promote STAT4 phosphorylation in murine T cells, although this effect was more pronounced in CD8 ϩ than in CD4 ϩ T cells (22) . A further examination comparing various subtypes of IFN-␣ demonstrated that although murine IFN-␣〈 could indeed induce weak STAT4 phosphorylation, it was insufficient to drive IFN-␥ production and Th1 development in murine CD4 ϩ T cells (24) . In a related study, Hilkens and colleagues demonstrated that even in human T cells IFN-␣␤-driven STAT4 activation was attenuated compared with the effects of IL-12 (25) . This study suggested that IL-12 was more efficient than IFN-␣␤ at promoting Th1 development in human CD4 ϩ T cells. One explanation was that IL-12 stimulation was able to maintain STAT4 phosphorylation over a longer period of time compared with IFN-␣␤. We have recently confirmed this observation in murine CD4 ϩ T cells (26) ; however, a molecular explanation for this difference in signaling between IFN-␣ and IL-12 has not been examined. At the core of this issue is whether IL-12 and IFN-␣␤ share redundant roles in Th commitment and whether there truly is a species-specific pathway that operates in human but not in murine T cells.
In this study, we have addressed this central issue by comparing the ability of IL-12 and IFN-␣␤ to direct the commitment of primary human CD4 ϩ T cells toward the Th1 fate. We found that IFN-␣ does not promote Th1 development from naive human CD4
ϩ T cells, and we have linked this developmental defect to the inability of IFN-␣ to induce sustained T-bet expression. Further, we demonstrate that in primary naive human CD4 ϩ T cells, T-bet expression is sufficient to drive Th1 commitment in a cytokineindependent manner. Thus, in contrast to previous reports, IFN-␣␤ does not promote Th1 development in the absence of IL-12 because of the lack of sustained T-bet expression, and this effect is consistent across species.
Materials and Methods

Human subjects
Peripheral blood (100 -120 ml) was obtained from healthy adults by venipuncture. Informed consent was obtained from each donor according to guidelines established by the Internal Review Board (University of Texas Southwestern Medical Center, Dallas, TX).
Mice
DO11.10 TCR transgenic mice were housed in specific pathogen-free conditions in accordance with guidelines established by the Institutional Animal Care and Use Committee (University of Texas Southwestern Medical Center).
Cytokines, Abs, and reagents
Recombinant human IL-12, IFN-␣A, IFN-␥, and anti-human IL-4 were purchased from R&D Systems. Recombinant human IL-18 was purchased from BioSource International. Recombinant human IL-2 was a generous gift from M. Bennett (University of Texas Southwestern Med. Center). Neutralizing anti-human IFNAR2 was purchased from Calbiochem. The PE-and TRI-COLOR-conjugated anti-human CD4, anti-human IFN-␥, antimurine-CD4, and anti-murine-IFN-␥ were purchased from Caltag Laboratories. FITC-conjugated anti-human CD45RA Ab and PE-conjugated antihuman IL-12R␤2 Abs were purchased from BD Pharmingen. Polyclonal rabbit anti-human STAT4, anti-human STAT1, and anti-human T-bet Abs were purchased from Santa Cruz Biotechnology. Anti-phospho-STAT4 was purchased from Zymed Laboratories, and anti-phospho-STAT1 was purchased from Upstate Biotechnology. HRP-conjugated goat anti-rabbit Ig antiserum was purchased from Jackson ImmunoResearch Laboratories.
Purification of hPBMCs and naive CD4 ϩ T cells from peripheral blood
Human PBMCs (hPBMCs) were isolated by Ficoll density centrifugation using lymphocyte separation medium (Cellgro) and cultured in complete IMDM supplemented with 10% FBS (Valley Biomedical) (cIMDM). hPBMCs used for purification of naive cells were stained with anti-human CD45RA-FITC and either anti-human CD4-PE or anti-human CD4-TRI-COLOR. Cells were sorted on a MoFlo cytometer (DakoCytomation) to Ͼ93% purity. Both hPBMCs and naive CD4 ϩ T cells were activated for 3 days at 1-5 ϫ 10 6 cells/ml in cIMDM containing 50 -100 U/ml recombinant human (rh)IL-2 using either 1 g/ml PHA (Calbiochem) or culture plates coated with 5 g/ml anti-CD3 (OKT3) and 5 g/ml anti-CD28 (clone 37.51). Cytokines and neutralizing anti-cytokine Abs were added at the following concentrations as indicated in the figures: rhIL-12, 10 ng/ml; rhIFN-␣A, 1,000 U/ml; rhIFN-␥, 10 ng/ml; rhIL-4, 10 ng/ml; anti-human IL-12 (clone 20C2), 5 g/ml; anti-human IFNAR2, 2-5 g/ml; anti-human IFN-␥ (clone 4SB3), 5 g/ml; and anti-human IL-4, 5 g/ml. On day 3, cells were split into cIMDM containing 50 U/ml rhIL-2 and rested until day 7. Restimulation was performed using either 0.8 g/ml PMA (A.G. Scientific) plus 1 M ionomycin (Sigma-Aldrich) or plates coated with 5 g/ml anti-CD3 (OKT3).
Intracellular cytokine and phospho-STAT4 staining
For intracellular cytokine staining, resting Th cells were restimulated with 0.8 g/ml PMA plus 1 M ionomycin for 4 h. Brefeldin A (1 g/ml; Epicentre Technologies) was added during the last 2 h of stimulation. For Th1 effector function assays, cells were stimulated with either PMA plus ionomycin, 10 ng/ml rhIL-12, 1,000 U/ml IFN-␣A, 50 ng/ml IL-18, or a combination of IL-12/IL-18 or IFN-␣A/IL-18. After stimulation, cells were harvested and intracellular cytokine staining was performed as previously described (21) .
Intracellular tyrosine-phosphorylated (P-Y) STAT4 was detected by intracellular staining as described (27) . Freshly isolated PBMCs were activated with cytokines as indicated in the text and were then incubated in 5% formalin/PBS followed by fixation in cold 100% methanol. Cells were washed extensively in staining buffer (PBS, 0.5% BSA, and 1 mM NaVO 4 ) followed by permeabilization in staining buffer containing 0.1% saponin. Cells were stained with 0.5 g of anti-STAT4 (clone SC-486; Santa Cruz Biotechnology) or with anti-phosphotyrosine STAT4 (Zymed Laboratories). A goat-anti-mouse Ig-biotin (Jackson ImmunoResearch Laboratories) was used for secondary detection followed by staining with streptavidin-PE-Cy5. Cells were also stained with anti-hCD4-PE and anti-hCD45RA-FITC. Cells were analyzed on a FACScan (BD Biosciences) and the data were processed through CellQuest software.
Analysis of cytoplasmic and nuclear STAT4
hPBMCs activated with IL-12 or IFN-␣ for various times were stained for CD4, CD45RA, and phosphotyrosine-STAT4 as described above and counterstained with 20 ng/ml propidium iodide. Alternatively, the biotinylated phosphotyrosine-STAT4 was stained with streptavidin-FITC and the nucleus was counterstained with 5 M DRAQ5 (Axxora). These cells were also stained with anti-hCD4-PE. Image files of 5,000 -10,000 events were collected for each sample using the ImageStream imaging flow cytometer (Amnis) and analyzed using IDEAS software (Amnis). In-focus single cells were identified by gating on propidium iodide or DRAQ5-positive events with high nuclear aspect ratios (minor to major axis ratio, a measure of circularity) and high nuclear contrast (as measured by the Gradient Max feature). CD4 ϩ CD45RA ϩ lymphocytes (low side scatter/low area cells) were then gated. Nuclear localization of phosphotyrosine-STAT4 within these cells was measured using the similarity score, which quantifies the correlation of pixel values of the nuclear and phosphotyrosine-STAT4 images on a per-cell basis (28) . If the transcription factor is nuclear, the two images will be similar and have large positive values. If it is cytoplasmic, the two images will be anti-similar and have large negative values. Events with positive values Ͼ1 had visually apparent nuclear distributions of transcription factor and were gated to quantify the percentage of cells within the CD4 ϩ CD45RA ϩ lymphocyte population with nuclear-localized phosphotyrosine-STAT4.
Quantitative real-time PCR (qPCR) analysis
Total RNA was extracted using the RNeasy Mini Kit (Qiagen) according to the manufacturer's instructions followed by reverse transcription. The resultant cDNA was subjected to qPCR analysis with SYBR Green Master Mix (Stratagene) on a ABI7300 real-time thermocycler (Applied Biosystems). Human GAPDH was used as a reference. Relative changes in mRNA expression were calculated by the 2 Ϫ⌬⌬CT method (29) , and all treatment groups were referenced to the unstimulated controls. The primers used to detect mRNA transcripts are as follows: hIFN-␥, 5Ј-TGATTACA AGGCTTTATCTCAGGG-3Ј (forward) and 5Ј-GGCAGTAACTGGATAG TATCACTTCAC-3Ј (reverse); hIL-12R␤2, 5Ј-ACCTTCCCACCCATGAT GGC-3Ј (forward) and 5Ј-GAAAACAGAAAGGGAGATGTGCTG-3Ј (reverse); hT-bet, 5Ј-CGTCCAACAATGTGACCCAG-3Ј (forward) and 5Ј-GCAGTCACGGCAATGAACTG-3Ј (reverse); and hGAPDH, 5Ј-AC ATCGCTCAGACACCATGG-3Ј (forward) and 5Ј-CATGTAGTTGAGGT CAATGAAGGG-3Ј (reverse).
Cytometric bead array and ELISA analyses of human cytokines
Naive human CD4 ϩ T cells were activated for 7 days as described above and then restimulated at 5 ϫ 10 5 cells/ml for 24 h on anti-CD3-coated plates. Supernatants were analyzed for IL-4, IL-5, and IFN-␥ cytokine concentrations by either cytometric bead arrays (BD Pharmingen) or ELISAs (eBioscience) according to the manufacturer's protocols.
Immunoprecipitation and immunoblotting
hPBMCs were stimulated and expanded for two consecutive weeks with PHA under Th1 conditions (10 ng/ml rhIL-12). On day 14, cells were washed in cIMDM and rested at 1 ϫ 10 7 cells/ml for 30 min at 37°C in 5% CO 2 . Cells were stimulated with either 10 ng/ml rhIL-12 or 1,000 U/ml rhIFN-␣A for the indicated periods of time at 37°C in 5% CO 2 . Lysis was performed for 1 h at 4°C in radioimmune precipitation assay buffer containing proteinase inhibitors. Samples were precleared using rabbit preimmune serum, and immunoprecipitation of human STAT4 was performed using 3 g per sample of rabbit anti-human STAT4 bound to protein GSepharose beads (Amersham Biosciences). Immunoprecipitates were resolved by electrophoresis with 7% SDS-polyacrylamide gel and transferred to polyvinylidene difluoride membranes (Bio-Rad). Western blotting was performed using rabbit anti-phosphorylated STAT4 with an HRP-conjugated goat anti-rabbit secondary Ab. Detection was performed using ECL detection reagents followed by exposure to Hyperfilm ECL (Amersham Biosciences). The membranes were then stripped and reprobed with antihuman STAT4 polyclonal antiserum followed by HRP-conjugated goat anti-rabbit Ig.
Retrovirus cDNA expression constructs
The full-length murine IFNAR2 cDNA was amplified from a cDNA clone (clone identifier: 4187603; Invitrogen Life Technologies) with the primers 5Ј-AAAAAGATCTAGCTGAGCAGGATGCG-TTCACGG-3Ј (forward) and 5Ј-AAAAAGATCTCTTTGGAGTCATCTCATGATGTAGCC-3Ј (reverse). The PCR product was digested with BglII and cloned into the BamHI site of a retrovirus vector expressing GFP (GFPRV). A full-length human T-bet cDNA clone (GenBank accession no. BC039739) was purchased from American Type Culture Collection. The open reading of this cDNA clone was amplified by PCR with the primers 5Ј-AAAACTCGAGCC CGGATGGGCATCGTGGAG-3Ј (forward) and 5Ј-AAAACTCGAGCTGC TCAGTTGGGAAAATAGTTATAAAACTGTCC-3Ј (reverse). The PCR product was digested with XhoI and ligated into the XhoI site within the retrovirus vector GFPRV (30) , and all constructs were confirmed by DNA sequencing.
Retroviral transduction of primary naive human CD4
ϩ T cells Retroviral supernatants were generated by transfection of the Phoenix amphotropic cell line as described (31) . Naive CD4 ϩ CD45RA ϩ human T cells were purified by cell sorting as described above. Purified cells were activated with plate-bound anti-CD3/anti-CD28 in complete medium with 600 U/ml hIL-2 for 24 h. The cells were subjected to two rounds of retroviral transduction by spinning the cells at 1,000 ϫ g for 90 min in the presence of retroviral supernatants containing 5 g/ml Polybrene. Twentyfour hours after the first round of retroviral transduction, cytokines or anticytokine Abs were added to the cultures as indicated in the text and figure legends. Cells were expanded on day 7 by restimulating the cells on anti-CD3 coated plates. The cells were rested until day 14 before intracellular cytokine analysis was conducted.
Retroviral transduction was performed in murine CD4 ϩ T cells as previously described (31) . Briefly, infectious retrovirus supernatants were generated in the Phoenix ecotropic packaging cell line transfected with retrovirus plasmids. DO11.10 splenic T cells were transduced with retrovirus supernatants supplemented with 2 mg/ml protamine sulfate and 10 ng/ml IL-12 to generate polarized Th1 cells. Transduced T cells were purified on day 7 after activation by flow cytometric sorting based on GFP expression. Purified cells were expanded by restimulation with OVA peptide and irradiated BALB/c splenocytes.
Results
IFN-␣ does not promote Th1 development in the absence of IL-12
We began this study by first assessing the ability of IFN-␣ to promote Th1 development within highly purified naive CD4 ϩ T cells. For these experiments, human CD4 ϩ CD45RA ϩ cells were sorted to Ͼ95% purity from peripheral blood obtained from healthy adult donors. Sorted cells were then immediately activated on plate-bound anti-CD3/anti-CD28-coated plates in the presence of either purified cytokines or neutralizing anti-cytokine mAbs. Seven days following primary activation, resting cells were restimulated with either PMA plus ionomycin (Fig. 1, A and D) or platebound anti-CD3 (Fig. 1 , B and C) and assessed for cytokine protein or mRNA expression. As shown in Fig. 1A , IL-12 was capable of enhancing IFN-␥ expression, and this effect was more pronounced when IL-4 was neutralized during primary stimulation (Fig. 1A,  condition 3 ). Further, IFN-␣ did not inhibit the ability of IL-12 to induce IFN-␥ expression either in the absence or presence of neutralizing anti-IL-4 Ab (Fig. 1A, condition 4) . Stimulation with IFN-␥ alone did not promote Th1 development (Fig. 1A , condition 5), as expected and as previously demonstrated (19, 32) . However, in contrast to previous reports (17, 22, 23) , IFN-␣ was also ineffective at promoting Th1 development in the absence of IL-12, and the percentage of cells capable of secreting IFN-␥ was less in IFN-␣-treated cells compared with neutralizing conditions (Fig.  1A , compare conditions 1 and 2). Further, cells primed with IFN-␣ did not induce IFN-␥ mRNA in response to anti-CD3 stimulation (Fig. 1B, condition 3) , indicating a general defect in Th1 commitment.
We considered the possibility that IFN-␣ was promoting Th2 development. To address this, purified naive human CD4 ϩ T cells were activated under polarizing conditions as described above, and IFN-␥, IL-4, and IL-5 secretion was measured by cytometric bead arrays (Fig. 1C) . IL-12 stimulation enhanced IFN-␥ secretion ( Each experiment described above was repeated at least three times. We observed heterogeneity in the overall percentages of cells that were capable of secreting IFN-␥ from one donor to the next. This level of heterogeneity in IFN-␥ expression is depicted in Fig. 1D . Here, naive CD4 ϩ CD45RA ϩ cells were purified from three separate healthy human donors and activated under neutralizing conditions (anti-IL-12 plus anti-IFNAR2; "Control" in Early reports demonstrating a role for IFN-␣ in Th1 development used mixed populations of peripheral or cord blood lymphocytes (13, 14) . Thus, it was possible that IFN-␣ was acting indirectly on other populations of cells to promote Th1 development in CD4 ϩ T cells. Therefore, we addressed this issue by attempting to reproduce those early studies. For these experiments, nonfractionated human PBMCs were activated with plate-bound anti-CD3 plus anti-CD28 in the presence of cytokines or neutralizing anticytokine Abs as indicated in Fig. 2A . Cells were expanded in culture for 7 days followed by restimulation with PMA and ionomycin to assess IFN-␥ expression by intracellular cytokine staining. IL-12 was sufficient to increase the percentage of CD4 ϩ T cells capable of secreting IFN-␥ as expected ( Fig. 2A, condition 3) , and the absence or presence of neutralizing anti-IL-4 Ab did not significantly enhance this effect. However, differentiation of human PBMCs in the presence of IFN-␣ alone was not sufficient to expand IFN-␥-secreting CD4 ϩ T cells compared with neutralizing conditions (Fig. 2A, compare conditions 1 and 2 ). Although IFN-␣ failed to enhance Th1 development, it did not inhibit the ability of IL-12 to expand a population of IFN-␥-secreting CD4 ϩ T cells ( Fig. 2A, condition 4) .
The differences observed between our data and previous reports could have resulted from our strict control of endogenous IL-12 levels with the use of neutralizing anti-IL-12 Abs with cells cultured in the presence of IFN-␣. In some cases, previous studies did not neutralize IL-12 during the primary activation (13, 14) . To address this, hPBMCs were activated in the presence of IL-12 or IFN-␣ in the absence or presence of neutralizing Abs for 7 days (Fig. 2B) . IFN-␥ expression from CD4 ϩ T cells was assessed as described above. Even in the absence of neutralizing Abs against IL-12, IFN-␣ alone was still unable to induce Th1 development in CD4 ϩ T cells (Fig. 2B , compare conditions 6 and 7).
We considered the possibility that subtypes of IFN-␣␤ other that IFN-␣A may differentially regulate Th1 commitment. To address this, naive human CD4 ϩ T cells were activated in parallel cultures with IFN-␣B2, IFN-␣D, IFN-␣A/D, and IFN-␤. Consistent with results obtained with IFN-␣A ( Figs. 1 and 2 ) and the other IFN-␣ subtypes (data not shown), IFN-␤ (Fig. 3A) failed to promote Th1 development. In each case, these cultures were activated with 1,000 U/ml IFN-␣␤. Previous reports demonstrating a role for IFN-␣␤ in murine Th1 development used IFN-␣ at concentrations ranging from 50,000 to 100,000 U/ml (22, 23) . Thus, it was possible that extremely high concentrations of IFN-␣␤ were required to promote Th1 development. However, we titrated IFN-␣A in primary stimulation cultures and found that IFN-␣A at concentrations up to 100,000 U/ml was still incapable of driving Th1 development in human CD4 ϩ T cells (Fig. 3B) . Studies of in vitro activated murine T cells suggest that repeated stimulation under Th1-polarizing conditions tends to reinforce Th1 commitment as measured by increased IFN-␥ secretion and the inability of these cells to be redirected to the Th2 phenotype (33). Based on these observations, we wished to determine whether repeated IFN-␣ stimulation could eventually lead to Th1 commitment. Naive human CD4 ϩ CD45RA ϩ T cells were purified and activated for 1 wk with plate-bound anti-CD3 plus anti-CD28 in the presence of cytokines or neutralizing anti-cytokine Abs as indicated in Fig. 3C (primary (1°) conditions) . These cells were then restimulated for a second week with either additional cytokines or neutralizing anti-cytokine Abs (secondary (2°) conditions). IFN-␥ mRNA was quantified from cells that were restimulated with either medium or PMA plus ionomycin. Cells that were stimulated for the first week with IL-12 displayed 3-to 4-fold induction of IFN-␥ mRNA compared with cells that were differentiated under neutralizing conditions during the primary and secondary stimulations (Fig. 3C, compare conditions 1 and 2) . However, cells that received IFN-␣ during the primary stimulation alone (Fig. 3C , condition 4) or during both the primary and secondary stimulations (Fig. 3C, condition 5 ) failed to induce IFN-␥ mRNA compared with cells polarized under neutralizing conditions (Fig. 3C, condition 1) . Although IFN-␣ failed to promote Th1 development in the absence of IL-12, it did not significantly inhibit IFN-␥ expression from cells differentiated in the presence of IL-12 during the primary stimulation (Fig. 3C, compare conditions 2 and 3 ; p ϭ 0.17). Collectively, these data demonstrate that IFN-␣ is not sufficient to promote Th1 development in human CD4 ϩ T cells.
Cytokine-driven STAT4 phosphorylation and acute IFN-␥ expression
IL-12 drives Th1 development in CD4 ϩ T cells by efficiently promoting STAT4 tyrosine phosphorylation (9, 34). In addition, IL-12, in synergy with IL-18, induces sustained secretion of IFN-␥ 
C, Purified naive CD4
ϩ T cells were activated as described above for 7 days (primary (1°) conditions) where "؉" indicates the addition of a cytokine and "Ϫ" indicates the addition of a neutralizing anti-cytokine Ab. These cells were then restimulated with plate-bound anti-CD3 under the cytokine conditions indicated in the figure for an additional 7 days (secondary (2°) conditions). Cells were then restimulated with either medium alone or PMA plus ionomycin for 1 h. Total RNA was isolated from these cells, and IFN-␥ mRNA induction was measured by qPCR. All data are referenced to the unstimulated control in condition 1. from Th1 cells that, in mice, has been shown to be dependent upon STAT4 (35) (36) (37) . Thus, IL-12-dependent STAT4 activation plays significant roles in both Th1 development and effector function. Although both IL-12 and IFN-␣␤ can promote STAT4 phosphorylation in human CD4 ϩ T cells (38, 39) , several reports have suggested that either the magnitude or the kinetics of IFN-␣-induced STAT4 phosphorylation is decreased compared with IL-12 signaling (25, 38) . Based on these observations, we wished to determine which aspects of Th1 development and effector function could be directly regulated by IFN-␣ through STAT4 activation.
First, the kinetics of IL-12-and IFN-␣-dependent STAT4 tyrosine phosphorylation were assessed in human PBMCs by immunoblotting (Fig. 4, A and B) . IL-12 stimulation of Th1-polarized PBMCs promoted STAT4 phosphorylation that was sustained up to 24 h poststimulation (Fig. 4A, upper panel, lanes 2-7) . In contrast, IFN-␣A-dependent STAT4 phosphorylation was attenuated (Fig. 4A, upper panel, lanes 8 -13) , peaking at 0.5-2 h and extinguished by 6 h (Fig. 4B, lanes 8 -13) . In addition, IFN-␣-dependent STAT1 phosphorylation was sustained up to 6 h poststimulation (Fig. 4A, lower panel, lanes 8 -13) , indicating that the rate at which STAT4 and STAT1 are dephosphorylated may be regulated through different mechanisms.
We wished to determine whether the kinetics of IFN-␣-dependent STAT4 tyrosine phosphorylation differed between fully polarized Th1 cells and uncommitted naive CD4 ϩ T cell progenitors. To address this, we assessed the kinetics of STAT4 tyrosine phosphorylation in naive CD4 ϩ CD45RA ϩ T cells within freshly isolated human PBMCs (Fig. 4, C-G) . For these experiments, both total STAT4 protein and P-Y STAT4 were measured by intracellular staining from cells activated with either IL-12 or IFN-␣ between 0 and 24 h. The overall expression of STAT4 protein in CD4 ϩ CD45RA ϩ cells was not altered by cytokine treatment (Fig.  4C ) and remained constant throughout the 24 h time course (data not shown). In naive CD4 ϩ CD45RA ϩ T cells, IL-12 did not increase the percentage of cells displaying elevated P-Y STAT4 compared with unstimulated cells (Fig. 4D) , presumably due to the lack of IL-12R␤2 expression (32) . However, IFN-␣ stimulation promoted STAT4 phosphorylation in naive CD4 ϩ T cells (Fig.  4D) . Further, consistent with our observations in Th1 cells (Fig. 4,  A and B) , we found that IFN-␣-driven STAT4 phosphorylation was rapidly induced by 30 min and then extinguished by 6 h poststimulation in naive CD4 ϩ T cells (Fig. 4, E and G) . Further, the kinetics of IFN-␣-dependent STAT4 phosphorylation was similar in the CD45RA ϩ and CD45RA Ϫ populations (Fig. 4, F and G) . We also observed that IL-12 promoted STAT4 phosphorylation in ϳ15-20% of the CD45RA Ϫ cells (Fig. 4F) , indicating that these cells were responsive to IL-12. Further, IL-12-dependent STAT4 phosphorylation was maintained in this population through the entire 24-h time course. Taken together, these data indicate that unlike IL-12, IFN-␣ does not promote sustained STAT4 tyrosine phosphorylation in naive human CD4 ϩ T cells. It was possible that the reason IFN-␣ failed to promote Th1 development was due to lack of sustained STAT4 phosphorylation. However, it was also possible that phosphorylated STAT4 was not efficiently translocated to the nucleus in response to IFN-␣. This possibility was addressed by visualizing the relative nuclear accumulation of phosphorylated STAT4 within naive human CD4 ϩ T cells (Fig. 4, H and I) . We used a novel technology that combines multiparametric flow cytometry with single cell microscopy. For these experiments, freshly isolated human PBMCs were stimulated with either IL-12 or IFN-␣ followed by intracellular staining for CD4, CD45RA, and P-Y STAT4 as described above. Cells were imaged with the use of an ImageStream flow cytometer. Single cell images were processed through the live, CD4
ϩ , and CD45RA ϩ gates. Cells that exhibited an increase in phosphorylated STAT4 signal were divided into populations that displayed either P-Y STAT4 cytoplasmic accumulation (Fig. 4H, left panel) or nuclear accumulation (Fig. 4H, right panel) . As shown in Fig. 4I , ϳ50% of the CD4 ϩ CD45RA ϩ P-Y STAT4 ϩ cells displayed accumulation of P-Y STAT4 in the nuclei in response to IFN-␣. Although the level of P-Y STAT4 was significantly diminished by 6 h (Fig.  4G) , the residual amount of P-Y STAT4 within those cells was still retained within the nucleus (Fig. 4I) . Thus, these data suggest that although IFN-␣-induced STAT4 phosphorylation was attenuated compared with IL-12, STAT4 nuclear translocation remained intact in naive human CD4 ϩ T cells. We wished to correlate the duration of IFN-␣-dependent STAT4 phosphorylation with Th1 effector function. IFN-␥ secretion by Th1 cells is regulated independently by both Ag activation and innate cytokines (36, 40, 41) (Fig. 5, A and B) . Stimulation with each cytokine alone failed to promote IFN-␥ secretion (Fig. 5B) as previously reported (36, 38) . However, if cells were stimulated for 24 h, the level of IFN-␥ secreted into the culture supernatants was significantly lower in response to IFN-␣ plus IL-18 as compared with IL-12 plus IL-18 (Fig. 5C ). These data correlate with the attenuated activation of STAT4 in response to IFN-␣ observed above.
Ectopic IFNAR2 expression enhances IFN-␣-dependent STAT4 phosphorylation and acute IFN-␥ secretion
Several mechanisms could account for the differential activation of STAT4 by IL-12 vs IFN-␣. First, IFN-␣ signaling may induce the expression of negative regulators of JAK/STAT signaling such as suppressor of cytokine signaling (SOCS) proteins or Ubp43. However, we found that SOCS mRNA induction was equivalent in cells activated with either IL-12 or IFN-␣ (data not shown). In addition to SOCS proteins, Ubp43 has recently been shown to specifically inhibit JAK kinase activation by the IFNAR (42), and Ubp43-deficient mice display enhanced antiviral and antibacterial responses to IFN-␣ signaling (43, 44) . We examined STAT4 activation and IFN-␥ secretion in Ubp43-deficient T cells but detected no differences in these parameters compared with strain-matched wild-type control T cells (data not shown).
Previous studies have suggested that acute IFN-␣␤ signaling negatively regulates expression of the human IFNAR1 subunit, thereby extinguishing downstream signaling events (25) . However, Berenson et al. found that the murine IFNAR1 subunit was stably expressed on murine CD4 ϩ T cells following IFN-␣ activation (26) . This recent study concluded that, as in human T cells, STAT4 tyrosine phosphorylation was attenuated in response to IFN-␣ compared with IL-12. Further, we recently demonstrated that the IFNAR2 subunit plays an important role in STAT4 activation (45) . In that study, we found that the STAT4 N-domain interacts with the cytoplasmic domain of the IFNAR2 subunit. Based on these collective observations, we wished to determine whether ectopic overexpression of either the IFNAR1 or IFNAR2 subunit could restore IFN-␣-dependent STAT4 activation in murine T cells. To test this, we expressed the full length murine IF-NAR1 and IFNAR2 subunits in murine Th1 cells and tested both the kinetics of STAT4 phosphorylation and acute IFN-␥ secretion in response to IFN-␣. Retroviral expression of the IFNAR1 did not alter either the kinetics of STAT4 phosphorylation or the secretion of IFN-␥ in response to IFN-␣ plus IL-18 stimulation (data not shown). However, as shown in Fig. 6A , we found that expression of the IFNAR2 subunit increased both the magnitude and duration of IFN-␣-dependent STAT4 tyrosine phosphorylation. In contrast, IL-12-induced STAT4 activation was not altered by expression of the IFNAR2 subunit. The increased duration of STAT4 activation correlated well with enhanced induction of IFN-␥ in response to IFN-␣ plus IL-18 stimulation (Fig. 6B) . Here, purified transduced cells were activated for 24 h with either IL-12 plus IL-18 or with IFN-␣ plus IL-18 to assess IFN-␥ secretion. IL-12 plus IL-18 activated cells displayed ϳ60% IFN-␥ ϩ cells, and this effect was independent of the expression of the IFNAR2 subunit. However, we found that expression of the IFNAR2 subunit increased the IFN-␥ ϩ population by 10-fold in response to IFN-␣ plus IL-18 activation (Fig. 6, B and C) .
Differential induction of T-bet expression by IL-12 and IFN-␣
The differential kinetics of STAT4 phosphorylation observed in response to IL-12 and IFN-␣ could result in differences in the commitment of naive human CD4 ϩ T cells to the Th1 phenotype. One aspect of Th1 commitment is the acquisition of IL-12 responsiveness mediated through induction of the IL-12R␤2 subunit (46, 47) . Because both IL-12 and IFN-␣ have been reported to induce IL-12R␤2 expression (32), we examined whether IL-12 and IFN-␣ differed in their induction of IL-12R␤2 in developing human CD4 ϩ T cells. For these experiments, naive human CD4 ϩ CD45RA ϩ cells were purified from human peripheral blood and activated with plate-bound anti-CD3 plus anti-CD28 with the cytokines or neutralizing anti-cytokine Abs indicated in Fig. 7 . When analyzed at 48 h poststimulation, both IL-12 and IFN-␣ were able to promote expression of IL-12R␤2 cell surface protein (Fig. 7A ) and mRNA transcripts (Fig. 7B, upper panel) to similar levels. In addition, IL-12 plus IFN-␣ acted synergistically to promote enhanced IL-12R␤2 expression at 48 h (Fig. 7, A, and B, upper  panel) . However, IFN-␣ failed to maintain IL-12R␤2 expression in cells activated for 7 days (Fig. 7B) .
In mice, T-bet is known to be involved in the regulation of IL-12R␤2 (46, 48) (Fig. 7B, lower panel) . However, T-bet expression was not maintained in response to IFN-␣ alone in fully polarized cells analyzed on day 7 (Fig. 7B, lower panel) . The low expression of T-bet mRNA in response to IFN-␣ correlated well with decreased T-bet protein accumulation in these cells (Fig. 7C) .
Based on these observations, we considered the possibility that IFN-␣ failed to promote Th1 development because of the lack of stable T-bet expression within polarized Th cells. If this hypothesis is correct, then Th1 development should be restored by ectopic T-bet expression regardless of initial polarizing conditions. To test this hypothesis, we expressed T-bet by retroviral transduction of primary naive human CD4 ϩ T cells (Fig. 8 ). For these experiments, purified CD4 ϩ CD45RA ϩ T cells were activated with platebound anti-CD3 plus anti-CD28 and transduced with retrovirus constructs expressing GFP only (GFPRV) or human T-bet and GFP (hT-bet-GFP). Upon retroviral transduction, polarizing cytokine conditions were imposed with the addition of cytokines or neutralizing anti-cytokine Abs as indicated in Fig. 8 . These cells were expanded on day 7 with plate-bound anti-CD3, and IFN-␥ expression was assessed on day 14 by intracellular cytokine staining. We were able to achieve ϳ15-20% transduction efficiency as measured by GFP expression, and the non-GFP expressing cells served as an additional internal negative control. As shown in Fig.  8A , cells transduced with the hT-bet-GFP construct were gated on GFP Ϫ and GFP ϩ populations. Within the GFP-population, IL-12 increased the frequency of IFN-␥ ϩ cells whereas IFN-␣ did not promote IFN-␥ expression, as expected. However, expression of T-bet within the GFP ϩ population increased the percentage of cells capable of secreting IFN-␥, and this effect was independent of initial cytokine conditions (Fig. 8A, compare left and right panels) . Expression of GFP alone from the GFPRV had little effect on IFN-␥ expression (Fig. 8B) . Further, T-bet was sufficient to promote IFN-␥ expression even when cells were polarized under Th2-inducing conditions (Fig. 8, A, bottom panels, and B, condition 8). Thus, these data place T-bet downstream of STAT4 and suggest that T-bet is sufficient to mediate Th1 development in Analysis of IL-12R␤2 and T-bet transcript levels was performed by qPCR using the primers listed in Materials and Methods. Transcript levels for each condition were normalized to GAPDH, and the data were further normalized relative to cells activated under neutralizing conditions. C, Whole-cell lysates were prepared from day 7 activated cells and assessed for expression of T-bet protein by Western blotting (upper panel). Blots were stripped and re-probed for lamin protein expression (lower panel).
human CD4
ϩ T cells independently of innate cytokine priming. These data also suggest that IFN-␣ fails to mediate Th1 development because of a lack of sustained T-bet expression.
Discussion
Type I IFN is one of the first lines of defense against many viral and some bacterial infections. In recent years, the importance of type I IFN during innate responses has been highlighted by the discovery of IFN-␣-secreting plasmacytoid dendritic cells (53, 54) as well as TLR signaling pathways that promote IFN-␣␤ secretion from innate cells (1, 2) . Thus, IFN-␣␤ represents an innate cytokine with the potential to shape adaptive immune responses. Further, in vitro virus infection of human plasmacytoid dendritic cells promotes their differentiation into high IFN-␣␤-producing cells (55) , suggesting a role for these cells in regulating adaptive responses. However, in the absence of other innate signals the ability of IFN-␣␤ to promote Th1 development is controversial. The role of IFN-␣␤ in promoting type I responses has been suggested by studies of lymphocytic choriomeningitis virus (LCMV) infections in mice (22) . In that study, Biron and colleagues correlated the induction of IFN-␥ from splenocytes with LCMV infection that was IFN-␣␤-and STAT4-dependent but IL-12-independent. Collectively, these studies have concluded that, like IL-12, IFN-␣␤ can directly promote Th1 development through the activation of STAT4 in naive CD4 ϩ T cells. However, more recent studies raise the possibility that the effects of IFN-␣␤ observed in vivo might be more pronounced in CD8 ϩ than in CD4 ϩ T cells (21, 24, 25) . In this study, we found that, in the absence of IL-12, IFN-␣ was insufficient to promote Th1 development. This defect was correlated with attenuated STAT4 tyrosine phosphorylation and the lack of stable expression of the Th1-specific transcription factor T-bet. Whether STAT4 directly regulates the T-bet promoter in human CD4 ϩ T cells is unclear at this point. However, we found that ectopic expression of T-bet within primary naive human CD4 ϩ T cells circumvented the requirement for innate cytokines in Th1 commitment.
Although we found that IL-12 was sufficient to promote Th1 development, human CD4 ϩ T cells failed to commit to the Th1 fate in response to IFN-␣␤. In some cases, we also observed that cells cultured with IL-12 plus IFN-␣ expressed less IFN-␥ than cells differentiated with IL-12 alone. However, this effect was not consistent from one donor to the next. Nonetheless, we consistently observed that IFN-␣ alone failed to promote Th1 development and, in some cases, suppressed IFN-␥ expression compared with cells developing under neutralizing conditions. Given these results, how can our observations be reconciled with previous reports suggesting that IFN-␣␤ regulates type I responses in vivo? Clearly, there are many examples of virus infections that promote IFN-␣␤ secretion and generate populations of T cells capable of secreting IFN-␥ (22, 56 -59) . In such cases, adaptive antiviral responses rely heavily on the activation and expansion of CD8 ϩ cells that commit to IFN-␥ expression independently of either IL-12 or STAT4 (37). Thus, it is possible that the type I responses observed in vivo do not originate from CD4 ϩ cells but rely on other cell types such as CD8 ϩ and NK cells. Indeed, type I responses to certain viruses such as LCMV are diminished in mice deficient in STAT4 and IFN-␣␤ receptor signaling (22) . However, these defects were observed predominantly in the CD8 ϩ T cell compartment.
Alternatively, it is possible that IFN-␣, in combination with other innate cytokines, could promote CD4 ϩ Th1 development in vivo. Our data indicate only that IFN-␣ is insufficient to promote Th1 development. IFN-␣ may be necessary in vivo, in the context of other innate signals, to drive Th1 development when IL-12 is limiting. For example, IL-18 and IFN-␣ were demonstrated to be required for productive IFN-␥ responses from CD8 ϩ T cells during LCMV infections (60) . These data suggest that IFN-␣␤ collaborates with IL-18 to promote IFN-␥ secretion from CD8 ϩ T cells in vivo. However, the sufficiency of IFN-␣␤ to drive CD4 ϩ Th1 development in vivo has not been demonstrated. Taken together, our results suggest that IFN-␣␤ may act in synergy with IL-12 to positively regulate early stages of Th1 commitment but, in the absence of IL-12, IFN-␣␤ is insufficient to promote full commitment of human CD4
ϩ T cells to the Th1 lineage.
